This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Cervical Cancer in Focus
Fertility-Sparing Surgery in Cervical Cancer
Michelle Davis, MD, of Harvard Medical School and the Dana Farber Cancer Institue, discusses the two fertility-sparing treatment options for cervical cancer. (1:46)
Gynecologic Oncology Trials: Patients with Limited English Less Likely to Participate
Accrual of patients with limited English proficiency to gynecologic oncology trials is approximately 3-fold lower than for fluent English speakers. Trial inclusion criteria, time constraints, and lack of translated study documents are important enrollment barriers.
Rethinking Cervical Cancer Screening Guidelines for Older Adults
A large population-based study showed that older patients with newly diagnosed cervical cancer were more likely to have late-stage disease and had a substantially lower survival rate compared to younger patients, suggesting a need to re-assess screening guidelines.
Vaginal Intraepithelial Neoplasia: Risk Factors After Hysterectomy for CIN
A small retrospective study points to advanced age as an independent risk factor for vaginal intraepithelial neoplasia after hysterectomy for cervical intraepithelial neoplasia. Laser vaporization may be the best management approach to reduce risks of further recurrence.
Biomarkers in Cervical Cancer
"It's still very much in its infancy," says Susana Campos, MD, MPH, of Harvard University and Dana Farber Cancer Institute. In this video, she discusses the handful of biomarkers that are available at this time. (1:34)
Q&A with Dr. Hunter Holt: The Impact of Being Uninsured or Covered by Medicaid on Advanced Cervical Cancer Diagnosis
How much does being uninsured or covered by Medicaid explain racial and ethnic disparities in the diagnosis of advanced-stage cervical cancer? Dr. Hunter discusses what he and his colleagues learned.
In Locally Recurrent or Persistent Cervical Cancer, Preoperative Lymph Node Metastasis Predicts Disease Recurrence
Recurrence rates for invasive cervical cancer are high following first-line treatment. The presence of lymph node metastasis predicts recurrence following salvage surgery for locally recurrent or persistent cervical cancer.
HPV-Negative Cervical Cancer Needs More Attention and Research
HPV-negative cervical cancer research and progress has been overshadowed by progress for HPV-positive cervical cancer. Gaps in knowledge regarding biologic characteristics, biomarkers, classification, models, and therapeutic targets need to be addressed.
Less Than Half of Patients with Recurrent or Metastatic Cervical Cancer Receive Second-Line Therapy Following Disease Progressions
Cervical cancer remains an important cause of cancer mortality in the United States, and treatment options remain limited. Less than half of women with r/mCC receive second-line therapy, and second-line therapeutic approaches are inconsistent.